A5064665669- Multiple Myeloma Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Synthesis and Biological Evaluation
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Biosimilars and Bioanalytical Methods
- Chemotherapy-induced cardiotoxicity and mitigation
- Peptidase Inhibition and Analysis
- Lymphatic System and Diseases
- Neutropenia and Cancer Infections
- Childhood Cancer Survivors' Quality of Life
- Immunotherapy and Immune Responses
- Cancer Treatment and Pharmacology
- Immune Cell Function and Interaction
- Cancer survivorship and care
Amsterdam University Medical Centers
2020-2024
Amsterdam UMC Location Vrije Universiteit Amsterdam
2024
Vrije Universiteit Amsterdam
2020-2024
Cancer Center Amsterdam
2023-2024
BD Biosciences (United States)
2024
Teclistamab and other B-cell maturation antigen (BCMA)-targeting bispecific antibodies (BsAbs) have substantial activity in patients with heavily pretreated multiple myeloma (MM) but are associated a high rate of infections. BCMA is also expressed on normal plasma cells mature B cells, which essential for the generation humoral immune response. The aim this study was to improve understanding impact BCMA-targeting BsAbs immunity. teclistamab polyclonal immunoglobulins cell counts evaluated MM...
Abstract Purpose: Bispecific antibodies (BsAb) directed against B-cell maturation antigen (teclistamab) or the orphan G protein-coupled receptor GPRC5D (talquetamab) induce deep and durable responses in heavily pretreated patients with multiple myeloma. However, mechanisms underlying primary acquired resistance remain poorly understood. Experimental Design: The anti–multiple myeloma activity of teclistamab talquetamab was evaluated bone marrow (BM) samples from T-cell phenotype function were...
// Christie P.M. Verkleij 1 , * Kristine A. Frerichs Marloes Broekmans Saida Absalah Patricia W.C. Maas-Bosman Sandy Kruyswijk Inger S. Nijhof Tuna Mutis Sonja Zweegman and Niels W.C.J. van de Donk Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, The Netherlands Shared first authors Correspondence to: Donk, email: n.vandedonk@vumc.nl Keywords: multiple myeloma; bispecific antibody; immunotherapy; BCMA; CD38 Received: October 09, 2020 Accepted: 13, Published: November...
Teclistamab, a T-cell redirecting bispecific antibody (BsAb) targeting B-cell maturation antigen (BCMA), has marked activity in heavily pretreated multiple myeloma (MM) patients (overall response rate: 63.0%; at least very good partial [≥VGPR]: 59.4%; median progression-free survival [PFS]: 11.3 months).1, 2 Teclistamab treatment induces activation and production of proinflammatory cytokines such as interleukin-6 (IL-6).3 This increase frequently results systemic inflammatory syndrome...
<div>AbstractPurpose:<p>Bispecific antibodies (BsAb) directed against B-cell maturation antigen (teclistamab) or the orphan G protein-coupled receptor GPRC5D (talquetamab) induce deep and durable responses in heavily pretreated patients with multiple myeloma. However, mechanisms underlying primary acquired resistance remain poorly understood.</p>Experimental Design:<p>The anti–multiple myeloma activity of teclistamab talquetamab was evaluated bone marrow (BM) samples...
<p>Supplemental Tables S1-S3, Figures S1-S15</p>
<p>Supplemental Tables S1-S3, Figures S1-S15</p>
<div>AbstractPurpose:<p>Bispecific antibodies (BsAb) directed against B-cell maturation antigen (teclistamab) or the orphan G protein-coupled receptor GPRC5D (talquetamab) induce deep and durable responses in heavily pretreated patients with multiple myeloma. However, mechanisms underlying primary acquired resistance remain poorly understood.</p>Experimental Design:<p>The anti–multiple myeloma activity of teclistamab talquetamab was evaluated bone marrow (BM) samples...
Abstract Background Patients, who discontinue early, do not benefit from phase I/II clinical trials (early-phase (EPCT)). In this study, associations between objective smartphone measurements of physical activity and fitness early trial discontinuation in patients with cancer participating EPCT were investigated. Methods Before start treatment, (steps/day) (meters walked 6 min) measured a smartphone, patient-reported function (PRO-PF) was assessed (EORTC QLQ-C30-PF). Early defined as ≤ 28...